SC
Basic Science (Poster)

Thursday, May 29, 2014: 7:00 PM-8:30 PM
Trinity Exhibit Hall
SC01
Atypical Fulminant Seronegative Neuromyelitis Optica in a Post-Renal Transplant Patient
Anteneh M Feyissa, MD, MSc., Univeristy of Texas Medical Branch at Galveston; Rahul Shah, MD, Univeristy of Texas Medical Branch at Galveston; Elena Shanina, MD, PhD, Univeristy of Texas Medical Branch at Galveston; Robert G Smith, MD, PhD, Univeristy of Texas Medical Branch at Galveston

PDF
SC02
Multiple Sclerosis Presenting with Bilateral Internuclear Ophthalmoplegia in a Patient with History of Dural Arteriovenous Fistula, Neurocysticercosis and Implanted Cardiac Pacemaker
Bardia Nourbakhsh, MD, University of Texas Southwestern Medical Center; William Renthal, MD PhD, University of Texas Southwestern Medical Center

PDF
SC03
Optical Coherence Tomographic Measures of Retinal Structure Do Not Correlate with Serum Vitamin D Levels in Multiple Sclerosis Patients
Bijal Mehta, MD, MPH, Harbor-UCLA Medical Center; Fawzi Abukhalil, MD, Harbor-UCLA Medical Center; Thong D Pham, MD, Harbor-UCLA Medical Center; Farah Villanueva, MD, Harbor-UCLA Medical Center; Celina Hayashi, BS, Claremont Colleges; Mark J Morrow, MD, Harbor-UCLA Medical Center


SC04
Vitamin A (retinoic acid) in Multiple Sclerosis: Avoiding the Mistakes Made with Vitamin D
Bijal Mehta, MD, MPH, UCLA


SC05
Autoimmune Limbic Encephalitis and Adult-Onset Type 1 Diabetes Caused By Anti-GAD65 Antibodies
Brittani L Conway, MD, University of Miami; Kottil Rammohan, MD, University of Miami


SC06
The Effects of Anti-Oxidant Supplements on Progression of MS: A Systematic Review of Human and Animal Studies for Clinicians and Patients
Camille A Juzwik, BSc, McGill University; Jason R Plemel, PhD, University of Calgary; Curtis A Benson, BSc, University of Alberta; Michelle Ploughman, PhD, Memorial University of Newfoundland


SC07
Clinical Characteristics and Imaging Features of Late Onset Multiple Sclerosis (LOMS)
Claudia Chaves, MD, Lahey Clinic; Rik Ganguly, BS, Lahey Clinic; Caitlin A Dionne, RN BSN MSCN, Lahey Clinic; Ann Camac, MD, Lahey Clinic

PDF
SC08
Might Misdiagnosis of Multiple Sclerosis Compromise Outcomes of Clinical Trials?
Collin F Mulcahy, MS2, The University of Texas Health Science Center at Houston Medical School; Jerry S Wolinsky, MD, The University of Texas Health Science Center at Houston Medical School; On Behalf Of The CombiRx Investigators, MD, MPH, PhD, RN, Icahn School of Medicine at Mount Sinai

PDF
SC09
Transfer of Kv1.3 Deficient T Cells with Stable Regulatory Properties Ameliorates EAE in a Manner That Is Partially Dependent on IL-2
Dominique M Tosi, MD, Johns Hopkins University; Inna V Grishkan, PhD, Johns Hopkins University; Melissa D Bowman, BA, Johns Hopkins University; Maya Harary, BS, Johns Hopkins University; Peter A Calabresi, MD, FAAN, Johns Hopkins University; Anne R Gocke, PhD, Johns Hopkins University


SC10
Evaluating the Outcomes of Fat Grafting for Lipoatrophy Defects in MS Patients Treated with Subcutaneous Disease-Modifying Therapies (DMT)
Donald A Graham, MD, University of Calgary; Michael Yeung, MD FRCPC, University of Calgary; David McKenzie, MD FRCSC, University of Calgary

PDF
SC11
Glioblastoma Multiforme in Multiple Sclerosis: A Diagnostic Challenge
Jaclyn R Duvall, MD, OU Medical Center; Saad Kanaan, M.D., OU Medical Center; Tania Reyna, M.D., OU Medical Center

PDF
SC12
Protective Environmental Risk Factors for Neuromyelitis Optica
Jennifer Graves, MD, PhD, UCSF Pediatric MS Center; Sirisha Grandhe, BA, UCSF Pediatric MS Center; Kelley M Weinfurtner, B.A., UCSF Pediatric MS Center; Lauren Krupp, MD, SUNY Stony Brook; Tanuja Chitnis, MD, Massachusetts General Hospital for Children; Jayne Ness, MD, Alabama Pediatric MS Center; Moses Rodriguez, MD, Mayo Clinic; Tim Lotze, MD, PhD, Texas Children's Hospital; Mark Gorman, MD, Partners Pediatric MS Center; Ellen Mowry, MD, MCR, Johns Hopkins Hospital; Maria Milazzo, NP, Stony Brook University Medical Center; Judith A James, MD, Oklahoma Medical Research Foundation, University of Oklahoma; T. Charles Casper, PhD, University of Utah; Emmanuelle Waubant, MD, PhD, UCSF Pediatric MS Center


SC13
Death Caused By Disseminated PML in a Natalizumab Treated MS Patient Whose Immune Competence Could Not be Restored
Malcolm H Gottesman, MD, Winthrop University Hospital; Stephen M Newman, MD, Island Neurological Associates PC; Tiffany M Harding, CCRC, MSCS, Winthrop University Hospital


SC14
It's Not As Simple As PML
Michelle A Allan, RN BA Nursing GCert MS, Monash Health

PDF
SC15
Diffusion Restricted Lesions in Multiple Sclerosis
Mirla Avila, MD, Texas Tech; Sasikant Gorantla, MD, Texas Tech; John DeToledo, MD, Texas Tech


SC16
A Study of Insulin Resistance in Multiple Sclerosis Subjects and Healthy Controls
Myla D Goldman, MD, University of Virginia; Scott Koenig, B.S., University of Virginia; Rebecca Yeamans, M.S., University of Virginia


SC17
Hypothalamic Lesion and Nmo-IgG Positivity Restricted to CSF
Parul Jindal, MD, OU Medical Center; Evgeny Sidorov, MD, OU Medical Center; Jaclyn R Duvall, MD, OU Medical Center; Tania Reyna, M.D., OU Medical Center

PDF
SC18
The Prevalence of Thyroid Autoantibodies in Multiple Sclerosis
Sinead McGowan, B.Sci., Fraser Health Multiple Sclerosis Clinic; Jacob (Jake) Reznik, student, Fraser Health Multiple Sclerosis Clinic; Galina Vorobeychik, MD, FRCPS(C), CMSC, Fraser Health Multiple Sclerosis Clinic


SC19
Neuromyelitis Optica Presenting as a Mass Lesion with Hydrocephalus (without Initial Myelitis or Optic Neuritis)
Thomas Shoemaker, MD, University of Pittsburgh Medical Center; Ryan L Orie, MPAS, PA-C, University of Pittsburgh Medical Center


SC20
Health-Related Quality of Life Instruments Used in Multiple Sclerosis Clinical Trials: A Systematic Review
Lixian Zhong, PhD, Biogen Idec; Xiaoli Niu, BS, University of Southern California; Sujata P. Sarda, PhD, Biogen Idec

PDF
See more of: CMSC
<< Previous Session | Next Session >>